SNAP25 synaptosome associated protein 25
ENSG00000132639 · protein coding · Open Targets profile
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- GO CC high conf, UniProt loc med conf, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.10440000146627426 (upper bound 0.26982998847961426). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against SNAP25 (botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxine), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Jonathan RubinSupernus Pharmaceuticals, Inc. · 3 of 3 trials Phase 2+
- Yan WuPeking University First Hospital · 3 of 3 trials Phase 2+Ph3NCT06583486 · A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Linesbrief
- David OzogHenry Ford Health · 2 of 3 trials Phase 2+
- Murad AlamNorthwestern University · 2 of 3 trials Phase 2+
- Christelle NGUYENOrganizational Affiliation: Université Paris Cité, Faculté de Santé | UFR de Médecine · 2 of 2 trials Phase 2+
- Cynthia ComellaRush University Medical Center · 2 of 2 trials Phase 2+
- Franck DurifUniversity Hospital, Clermont-Ferrand · 2 of 2 trials Phase 2+
- Geir BråthenSt. Olavs Hospital · 2 of 2 trials Phase 2+
- Joseph JankovicBaylor St. Luke's Medical Center · 2 of 2 trials Phase 2+
- Joseph T HullSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · 2 of 2 trials Phase 2+
- Richard B LiptonAlbert Einstein College of Medicine · 2 of 2 trials Phase 2+
- Stewart J TepperDartmouth-Hitchcock Medical Center · 2 of 2 trials Phase 2+
- Vivian SungWomen & Infants Hospital · 2 of 2 trials Phase 2+
- Rose KhavariHouston Methodist Research Group · 1 of 2 trials Phase 2+
- Abdelraouf ElmohsenDermatology, Venereology and Andrology Faculty of Medicine, Al-Azhar University · 1 of 1 trials Phase 2+
Registry trials of botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxine updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 334 of 370 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 30 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
133 trials of drugs against SNAP25 were stopped early; 12 give no reason
Terminated, withdrawn and suspended interventional trials of botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxine, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 133.
- withdrawn · 2026-11-03 · Vanderbilt University Medical Center · Botulinum Toxin Type A Injection [Botox]“Unable to secure funding for TMJ and masseter Botox.”
- withdrawn · 2026-10-06 · Centre Oscar Lambret · matched by the registry's drug synonyms“No recruitment”
- terminated · 2026-06-29 · Beth Israel Deaconess Medical Center · OnabotulinumtoxinA 145 UNT [Botox]“Failure to recruit subjects.”
- terminated · 2026-06-24 · University Hospital, Bordeaux · matched by the registry's drug synonyms“target number of patient not reached and lost of financial supplies”
- withdrawn · 2026-06-24 · houyajing · Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection“In accordance with the time-limit regulations for ethical review, since the ethical approval certificate of this study protocol has expired, I hereby formally apply for the withdrawal of this study from the clinical trial registration platform.”
- withdrawn · 2026-06-09 · University Hospital, Limoges · matched by the registry's drug synonymsNo reason given
- terminated · 2026-06-01 · University Hospital, Toulouse · matched by the registry's drug synonyms“Difficulties in recruiting patients”
- terminated · 2026-05-27 · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · matched by the registry's drug synonyms“Company/sponsor business decision; not due to or related to any safety concerns”
- terminated · 2026-05-22 · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · matched by the registry's drug synonyms“Company/sponsor business decision; not due to or related to any safety concerns”
- withdrawn · 2026-02-12 · University of Alabama at Birmingham · matched by the registry's drug synonyms“Not funded by industry”
- terminated · 2026-01-30 · Hospices Civils de Lyon · matched by the registry's drug synonyms“The Steering Committee decided on 22/09/2025 to end the project, due to persistent issues: enrolment suspended because of supply shortages and the arrival of alternative treatments, as well as the end of a key supply agreement.”
- suspended · 2026-01-26 · Northwell Health · matched by the registry's drug synonyms“Principal Investigator changing locations.”
- withdrawn · 2025-12-16 · Yale University · Botulinum toxin type A“Study never officially began (or enrolled)”
- terminated · 2025-12-10 · Centre Hospitalier Universitaire de Nīmes · matched by the registry's drug synonyms“Discontinuation of production of the investigational medicinal product (PRP)”
- terminated · 2025-12-09 · AbbVie · matched by the registry's drug synonyms“The study was terminated early due to lack of efficacy from the primary analysis results.”
- terminated · 2025-10-27 · Mayo Clinic · matched by the registry's drug synonyms“Enough data was collected to demonstrate device efficacy at interim analysis”
- withdrawn · 2025-09-10 · Lille Catholic University · Botulinum Toxin Type A 100U, Botulinum Toxin Type A 200U“discontinuation of the study”
- withdrawn · 2025-09-05 · University Hospitals Cleveland Medical Center · matched by the registry's drug synonyms“Lack of interest”
- terminated · 2025-08-20 · Mayo Clinic · matched by the registry's drug synonyms“Low Enrollment”
- withdrawn · 2025-07-18 · Montefiore Medical Center · matched by the registry's drug synonyms“It was determined that it would be impracticable to conduct this study as a randomized trial. Study has been repurposed as a non-randomized study.”
- terminated · 2025-05-13 · OHSU Knight Cancer Institute · Botulinum Toxin Type A“low enrollment”
- terminated · 2024-12-05 · University of Miami · matched by the registry's drug synonyms“Patient recruitment shortage and study coordinator turnover”
- withdrawn · 2024-10-21 · University of Kansas Medical Center · Botulinum Toxin Type A Injection [Botox]“Administrative-not IRB approved”
- terminated · 2024-09-27 · Brigitte Schürch · matched by the registry's drug synonyms“Lack of recruitment”
- terminated · 2024-09-20 · AEON Biopharma, Inc. · matched by the registry's drug synonyms“Study was terminated due to the analysis of the data not meeting the intended primary endpoint and key secondary endpoints.”
Paediatric incentives and obligations for SNAP25's drugs
For botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxine: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · SNAP25 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000232171 (Botulinum toxin type A, Treatment of skin wrinkling): W: decision granting a waiver in all age groups for all conditions or indications, 20 Mar 2025; EMEA-003202-PIP01-22 (Botulinum toxin type A, Treatment of skin wrinkling): W: decision granting a waiver in all age groups for all conditions or indications, 8 Jul 2022; EMEA-002628-PIP01-19 (Botulinum toxin type A, Prevention of post-operative atrial fibrillation in patients undergoing open-chest cardiac surgery): W: decision granting a waiver in all age groups for all conditions or indications, 10 Sept 2020; EMEA-002521-PIP01-18 (Botulinum toxin type A, Treatment of skin wrinkling): W: decision granting a waiver in all age groups for all conditions or indications, 16 Aug 2019; +1 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxineRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Boey: authorised since 15 Jul 2026; Nuceiva: authorised since 27 Sept 2019Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxineRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 140 interventional studies of botulinum toxin type a, incobotulinumtoxina, letibotulinumtoxina, prabotulinumtoxin a, abobotulinumtoxina, daxibotulinumtoxina, onabotulinumtoxina, trenibotulinumtoxine include patients under 18; 17 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 8 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.